Form 4: Artiva COO Jennifer Bush Sells Shares for Tax Obligations

Artiva Biotherapeutics COO Jennifer Bush sold 8,790 shares at an average price of $9.01 to satisfy tax withholding requirements following RSU vesting.

Summary

• Jennifer Bush, the Chief Operating Officer, Chief Legal Officer, and Compliance Officer of Artiva Biotherapeutics, sold 8,790 shares of common stock on May 19, 2026.
• The shares were sold at a weighted average price of $9.0078, with individual trade prices ranging from $8.7439 to $9.0104.
• The total value of the transaction was approximately $79,178.
• This sale was non-discretionary and conducted under a mandatory 'sell-to-cover' policy to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs).
• Following this transaction, Jennifer Bush remains a significant shareholder with 337,920 shares held directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves insider selling, the non-discretionary nature for tax purposes makes it a standard administrative occurrence.

Positives

• The sale was automatic and not a discretionary market trade, indicating it was not based on a negative outlook of the company.
• The reporting person retains a substantial majority of their equity, holding over 337,000 shares post-transaction.
• The use of a 'sell-to-cover' policy is a standard and transparent corporate governance practice for managing executive tax liabilities.

Negatives

• The transaction results in a slight reduction of the executive's total beneficial ownership.
• Public disclosure of insider selling, regardless of the reason, can sometimes create temporary negative pressure on stock sentiment.

Risks

• Market participants may misinterpret the automatic sale as a lack of confidence if they do not review the specific footnotes regarding tax withholding.
• Future RSU vestings will likely trigger additional automatic sales, which could lead to recurring sell-side volume from insiders.

Future Outlook

The executive is expected to continue participating in the company's equity incentive programs, with future vestings likely resulting in similar automatic tax-related sales under the established corporate policy.

Management Comments

• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are ubiquitous in the biotech industry, where high-growth companies use equity to attract and retain C-suite talent. These transactions are generally ignored by institutional analysts as they do not signal fundamental changes in company prospects.

Comparison to Industry Standards

• The retention of over 97% of the vested position is consistent with high-conviction insider behavior seen at peers like Fate Therapeutics.
• The transparency of the weighted average price disclosure meets the high-standard reporting requirements typical of Nasdaq-listed clinical-stage biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders should view this as a routine part of executive compensation with no impact on company operations or strategy.

Next Steps

• Monitor for subsequent Form 4 filings to track the vesting schedule of other key executives.

Key Dates

Recommendation

The filing reflects routine insider activity related to compensation rather than a strategic shift. The executive remains heavily invested in the company, supporting a continued hold rating based on this specific data point.

Keywords

Artiva Biotherapeutics, ARTV, Insider Selling, Form 4, Jennifer Bush, Biotechnology, RSU Vesting, Sell-to-Cover, Executive Compensation